ATE489108T1 - Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie - Google Patents

Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie

Info

Publication number
ATE489108T1
ATE489108T1 AT99956525T AT99956525T ATE489108T1 AT E489108 T1 ATE489108 T1 AT E489108T1 AT 99956525 T AT99956525 T AT 99956525T AT 99956525 T AT99956525 T AT 99956525T AT E489108 T1 ATE489108 T1 AT E489108T1
Authority
AT
Austria
Prior art keywords
tumor
flt4
vegfr
imaging
target
Prior art date
Application number
AT99956525T
Other languages
English (en)
Inventor
Kari Alitalo
Arja Kaipainen
Reija Valltola
Lotta Jussila
Original Assignee
Vegenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/169,079 external-priority patent/US6824777B1/en
Application filed by Vegenics Ltd filed Critical Vegenics Ltd
Application granted granted Critical
Publication of ATE489108T1 publication Critical patent/ATE489108T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT99956525T 1998-10-09 1999-10-08 Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie ATE489108T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/169,079 US6824777B1 (en) 1992-10-09 1998-10-09 Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
PCT/US1999/023525 WO2000021560A1 (en) 1998-10-09 1999-10-08 Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY

Publications (1)

Publication Number Publication Date
ATE489108T1 true ATE489108T1 (de) 2010-12-15

Family

ID=22614189

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99956525T ATE489108T1 (de) 1998-10-09 1999-10-08 Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie

Country Status (13)

Country Link
US (4) US8444957B2 (de)
EP (1) EP1119371B1 (de)
JP (5) JP4841724B2 (de)
CN (1) CN100340291C (de)
AT (1) ATE489108T1 (de)
AU (2) AU774266B2 (de)
CA (1) CA2345276C (de)
DE (1) DE69942981D1 (de)
DK (1) DK1119371T3 (de)
ES (1) ES2357406T3 (de)
NO (1) NO20011759L (de)
NZ (2) NZ529063A (de)
WO (1) WO2000021560A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
PT848755E (pt) 1995-09-08 2003-12-31 Genentech Inc Proteina relacionada com o vegf
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
DK1119371T3 (da) * 1998-10-09 2011-03-07 Vegenics Ltd Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
EP1553414A1 (de) * 1999-04-13 2005-07-13 Medarex, Inc. Methoden zur Diagnose und Behandlung metastasierender Prostata-Tumore
ATE377081T1 (de) 2000-02-25 2007-11-15 Ludwig Inst Cancer Res Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
US7273751B2 (en) 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CN1494552A (zh) 2001-01-19 2004-05-05 ·��ά��֢�о�Ժ Flt4(VEGFR-3)作为靶用于肿瘤成像和抗肿瘤治疗
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1411983A4 (de) * 2001-06-26 2006-06-21 Imclone Systems Inc Bispezifische antikörper, die an vegf-rezeptoren binden
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1432724A4 (de) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc Durch rna-interferenz vermittelte inhibierung von map-kinase-genen
US8003613B2 (en) 2003-11-17 2011-08-23 University Of Florida Research Foundation, Inc. Methods and compositions for inducing apoptosis
EP1713915B1 (de) 2004-02-10 2009-12-16 Sirna Therapeutics, Inc. RNA-INTERFERENZ-VERMITTELTE HEMMUNG DER GENEXPRESSION UNTER VERWENDUNG MULTIFUNKTIONELLER siNA (SHORT INTERFERING NUCLEIC ACID)
US20060024302A1 (en) 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
AU2006279462A1 (en) 2005-08-15 2007-02-22 Vegenics Limited Modified VEGF and PDGF with improved angiogenic properties
US9201063B2 (en) 2006-11-16 2015-12-01 General Electric Company Sequential analysis of biological samples
US7629125B2 (en) 2006-11-16 2009-12-08 General Electric Company Sequential analysis of biological samples
US8305579B2 (en) * 2006-11-16 2012-11-06 Thomas Pirrie Treynor Sequential analysis of biological samples
US9677125B2 (en) 2009-10-21 2017-06-13 General Electric Company Detection of plurality of targets in biological samples
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2911681A1 (de) 2012-10-26 2015-09-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Lyve-1-antagonisten zur vorbeugung oder behandlung eines pathologischen leidens in zusammenhang mit lymphangiogenese
WO2014124487A1 (en) 2013-02-18 2014-08-21 Vegenics Pty Limited Ligand binding molecules and uses thereof
EP2994758B1 (de) 2013-05-08 2017-12-20 Opthea Limited Biomarker für altersbedingte makuladegeneration (amd)
KR102131370B1 (ko) 2013-10-18 2020-07-08 삼성전자주식회사 Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
DE3587657D1 (de) 1984-01-30 1993-12-23 Imp Cancer Res Tech Verbesserungen an wachstumsfaktoren.
ES2006109A6 (es) 1987-03-11 1989-04-01 Erba Carlo Spa Un procedimiento para preparar un conjugado de inmunoglobulina.
EP1762623A1 (de) 1988-01-22 2007-03-14 ZymoGenetics, Inc. Verfahren zur Produktion von biologisch aktiven Peptiddimeren
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5198359A (en) 1989-03-07 1993-03-30 Boehringer Ingelheim International Gmbh Recombinant protein receptor for il-2
EP0474744B1 (de) 1989-05-22 1994-08-03 Zymogenetics, Inc. Pdgf-alpha-rezeptor
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
WO1992013867A1 (en) 1991-01-31 1992-08-20 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US5256766A (en) 1991-02-19 1993-10-26 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
DE69232718T2 (de) 1991-02-22 2003-04-03 American Cyanamid Co Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
US5231001A (en) 1991-03-14 1993-07-27 The United States Of America As Represented By The Department Of Health And Human Services Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5185438A (en) 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5270458A (en) 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
KR940703857A (ko) 1992-01-09 1994-12-12 티모 에스코 타이, 새로운 내피 세포 수용체 티로신 키나제(tie, a novel endothelial cell receptor tyrosine kinase)
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
WO1993015201A1 (en) 1992-01-22 1993-08-05 New England Deaconess Hospital Novel protein tyrosine kinases
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US5776755A (en) 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
HU221343B1 (en) 1992-10-28 2002-09-28 Genentech Inc Use of anti-vegf antibodies for the treatment of cancer
US5712395A (en) 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
DE4337197C1 (de) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
DE69434538T2 (de) 1994-03-08 2006-08-10 Human Genome Sciences, Inc. Vaskulärer endothelialer Wachstumsfaktor 2
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
DE69534996T2 (de) * 1994-06-09 2007-05-10 Licentia Oy Monoklonaler antikörper gegen flt4-rezeptor-tyrosin-kinase und dessen verwendung zur diagnose und therapie
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
WO1998033917A1 (en) 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
PT848755E (pt) 1995-09-08 2003-12-31 Genentech Inc Proteina relacionada com o vegf
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998005293A2 (en) * 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
DK2107109T3 (da) 1996-08-23 2012-09-24 Vegenics Pty Ltd Rekombinant vaskulær endotelcelle-vækstfaktor D (VEGF-D)
CN1345247A (zh) 1997-12-24 2002-04-17 路德维格癌症研究所 表达血管内皮生长因子d的表达载体和细胞系以及治疗黑素瘤的方法
DK1119371T3 (da) * 1998-10-09 2011-03-07 Vegenics Ltd Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi
KR101681886B1 (ko) 2015-04-06 2016-12-12 서울대학교산학협력단 지르코니아 결합능을 가지는 펩타이드

Also Published As

Publication number Publication date
DK1119371T3 (da) 2011-03-07
EP1119371A1 (de) 2001-08-01
AU2004208675A1 (en) 2004-09-30
NZ529063A (en) 2005-07-29
JP2012019790A (ja) 2012-02-02
CN100340291C (zh) 2007-10-03
JP2011121957A (ja) 2011-06-23
JP2002527404A (ja) 2002-08-27
US20160184405A1 (en) 2016-06-30
AU774266B2 (en) 2004-06-24
JP5642637B2 (ja) 2014-12-17
US20140072511A1 (en) 2014-03-13
CA2345276C (en) 2011-03-29
WO2000021560A9 (en) 2000-09-21
WO2000021560A1 (en) 2000-04-20
AU2004208675B2 (en) 2006-03-02
JP2015157829A (ja) 2015-09-03
CA2345276A1 (en) 2000-04-20
NZ511408A (en) 2004-04-30
US20150158928A1 (en) 2015-06-11
US8444957B2 (en) 2013-05-21
AU1312100A (en) 2000-05-01
NO20011759D0 (no) 2001-04-06
ES2357406T3 (es) 2011-04-26
JP4841724B2 (ja) 2011-12-21
JP5784310B2 (ja) 2015-09-24
NO20011759L (no) 2001-06-11
JP2013209382A (ja) 2013-10-10
CN1329504A (zh) 2002-01-02
DE69942981D1 (de) 2011-01-05
EP1119371B1 (de) 2010-11-24
US20100278736A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
ATE489108T1 (de) Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
NO20033285L (no) FLT4(VEGFR-3) som et mål for tumoravbildning og anti-tumor terapi
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
WO1997005250A3 (en) Receptor ligand vegf-c
CY1112101T1 (el) Νευροτροφικοι παραγοντες
PT1047781E (pt) Receptores de il-18
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
NO20002777D0 (no) FremgangsmÕte for bekjempelse av fedme
UA72875C2 (uk) БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ
AU6308801A (en) Mu-1, member of the cytokine receptor family
GB9811260D0 (en) Novel compounds
CY1105820T1 (el) Basb027 πρωτεϊνες και γονιδια απο moraxella catarrhalis, αντιγονα, αντισωματα και χρησεις
EP0821060A3 (de) E-Cadherin-Mutationen als Grundlage zur Diagnostik und Therapie humaner maligner Tumoren
GB9820003D0 (en) Novel compounds
WO2000023589A3 (en) Proliferation and apoptosis related proteins
GB9809683D0 (en) Novel compounds
GB9810285D0 (en) Novel compounds
GB9812163D0 (en) Novel compounds
GB9812440D0 (en) Novel compounds
DE69942767D1 (de) Gbs toxin rezeptor
GB9918208D0 (en) Novel compounds
WO2003016479A3 (en) Excitatory glycine receptors and methods
AU2002360392A8 (en) New gene expressed in prostate cancer and methods of use
GB0025170D0 (en) Novel compounds
GB9918302D0 (en) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1119371

Country of ref document: EP